Are You Using Real-World Evidence?

This e-book provides strategic insights and best practices for leveraging Real-World Evidence (RWE) across early asset planning, and clinical development to meet regulatory expectations and demonstrate value in the medical marketplace. Highlighting recent Parexel projects, the e-book showcases RWE’s impact in enhancing decision-making, reducing costs, and accelerating development timelines.

Emphasizing RWE’s role in identifying biomarkers, simulating external control arms, and supporting health technology assessments (HTAs), the guide underscores that RWE’s full potential is realized early in development. By integrating RWE across the product lifecycle, from designing innovative trials to post-marketing safety surveillance, Parexel demonstrates how RWE transforms traditional development phases into a cohesive continuum.

RWE-driven innovations include novel trial designs utilizing computer-modeled external control arms. Leveraging diverse data sources—electronic health records, claims data, registries, and literature—RWE employs advanced statistical methodologies like AI and Bayesian modeling to deepen understanding of disease conditions and therapeutic impacts. Learn more about the use of RWE in drug development by downloading the e-book below.